Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Didier Blaise

Showing results (71-80 of 510) with videos related to

Pageof 51
Sort By:
American Journal of Hematology|September 16, 2014
Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patientsRaynier Devillier, Véronique Gelsi-Boyer, Anne Murati, et al.
Bone Marrow Transplantation|September 5, 2020
Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMTFrédéric Baron, Myriam Labopin, Didier Blaise, et al.
Haematologica|February 5, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow TransplantationMohamad Mohty, Myriam Labopin, Reza Tabrizzi, et al.
Leukemia & Lymphoma|July 5, 2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimenColombe Saillard, Roberto Crocchiolo, Sabine Furst, et al.
Leukemia & Lymphoma|October 23, 2012
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemiaRaynier Devillier, Roberto Crocchiolo, Anne Etienne, et al.
Experimental Hematology|March 7, 2013
Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantationAngela Granata, Luca Castagna, Roberto Crocchiolo, et al.
International Journal of Cancer|January 6, 2010
Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experienceJacques-Olivier Bay, Aurélie Cabrespine-Faugeras, Reza Tabrizi, et al.
American Journal of Hematology|November 4, 2014
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogeneticsRaynier Devillier, Sarah Bertoli, Thomas Prébet, et al.
Haematologica|December 9, 2016
Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationFrédéric Baron, Mohamad Mohty, Didier Blaise, et al.
Transplantation and Cellular Therapy|August 14, 2022
Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHDColombe Saillard, Pierre-Henri Legal, Sabine Furst, et al.
Pageof 51

Showing results (71-80 of 510) with videos related to

Sort By:
Pageof 51
American Journal of Hematology|September 16, 2014
Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patientsRaynier Devillier, Véronique Gelsi-Boyer, Anne Murati, et al.
Bone Marrow Transplantation|September 5, 2020
Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMTFrédéric Baron, Myriam Labopin, Didier Blaise, et al.
Haematologica|February 5, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow TransplantationMohamad Mohty, Myriam Labopin, Reza Tabrizzi, et al.
Leukemia & Lymphoma|July 5, 2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimenColombe Saillard, Roberto Crocchiolo, Sabine Furst, et al.
Leukemia & Lymphoma|October 23, 2012
Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemiaRaynier Devillier, Roberto Crocchiolo, Anne Etienne, et al.
Experimental Hematology|March 7, 2013
Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantationAngela Granata, Luca Castagna, Roberto Crocchiolo, et al.
International Journal of Cancer|January 6, 2010
Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experienceJacques-Olivier Bay, Aurélie Cabrespine-Faugeras, Reza Tabrizi, et al.
American Journal of Hematology|November 4, 2014
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogeneticsRaynier Devillier, Sarah Bertoli, Thomas Prébet, et al.
Haematologica|December 9, 2016
Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationFrédéric Baron, Mohamad Mohty, Didier Blaise, et al.
Transplantation and Cellular Therapy|August 14, 2022
Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHDColombe Saillard, Pierre-Henri Legal, Sabine Furst, et al.
Pageof 51